Detalhe da pesquisa
1.
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis.
BMC Cancer
; 21(1): 1244, 2021 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34798846
2.
CD57 in human natural killer cells and T-lymphocytes.
Cancer Immunol Immunother
; 65(4): 441-52, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26850637
3.
Compartmentalization of immunosenescence: a deeper look at the mucosa.
Biogerontology
; 17(1): 159-76, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26689202
4.
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis.
Dermatol Ther (Heidelb)
; 11(5): 1839-1849, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34490549
5.
Adaptive NKG2C+CD57+ Natural Killer Cell and Tim-3 Expression During Viral Infections.
Front Immunol
; 9: 686, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29731749